Skip to main content

Advertisement

SpringerLink
Log in

Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer

  • Evolving Therapies (RM Bukowski, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Papillary renal cell cancer (RCC) constitutes approximately 10 % of renal cancers and is the commonest form after clear cell RCC, which accounts for approximately 75 % of cases. Until recently, most clinical trials in RCC were open to patients of all histologic types. Very recent clinical trials have been performed predominately in patients with clear cell RCC and relatively few trials have been done for patients with papillary RCC. The clinical characteristics of papillary RCC are less well appreciated because of both its relative rarity in the general oncology population and the lack of related clinical studies. This article reviews papillary RCC as a clinical entity separate from clear cell RCC. The MET signaling pathway, its association with increased invasion and progression of human cancer, and its dysregulation in papillary RCC is discussed. Lastly, foretinib, a multitargeted receptor tyrosine kinase inhibitor of several receptors, including MET and vascular endothelial growth factor receptor 2, is described in preclinical and phase I studies as well as in a phase II study in papillary RCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Paper of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bennington JL, Beckwith JB. Tumors of the kidney, renal pelvis, and ureter. Washington: Armed Forces Institute of Pathology; 1975.

    Google Scholar 

  2. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.

    Article  PubMed  CAS  Google Scholar 

  3. Blath RA, Mancilla-Jimenez R, Stanley RJ. Clinical comparison between vascular and avascular renal cell carcinoma. J Urol. 1976;115:514–9.

    PubMed  CAS  Google Scholar 

  4. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976;38:2469–80.

    Article  PubMed  CAS  Google Scholar 

  5. Kovacs G, Wilkens L, Papp T, de Riese W. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst. 1989;81:527–30.

    Article  PubMed  CAS  Google Scholar 

  6. Kovacs G. Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol. 1989;134:27–34.

    PubMed  CAS  Google Scholar 

  7. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosom Cancer. 1991;3:249–55.

    Article  PubMed  CAS  Google Scholar 

  8. Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors. Morphologic, cytochemical, and genotypic features. Cancer. 1995;76:669–73.

    Article  PubMed  CAS  Google Scholar 

  9. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res. 1993;62:89–124.

    Article  PubMed  CAS  Google Scholar 

  10. Balint I, Szponar A, Jauch A, Kovacs G. Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol. 2009;62:892–5.

    Article  PubMed  CAS  Google Scholar 

  11. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–3.

    Article  PubMed  CAS  Google Scholar 

  12. Kuroda N, Toi M, Hiroi M, Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18:487–94.

    PubMed  CAS  Google Scholar 

  13. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71–7.

    Article  PubMed  Google Scholar 

  14. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol. 1997;21:621–35.

    Article  PubMed  CAS  Google Scholar 

  15. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.

    Article  PubMed  CAS  Google Scholar 

  16. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24.

    Article  PubMed  Google Scholar 

  17. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59:532–7.

    Article  PubMed  Google Scholar 

  18. Ljungberg B, Alamdari FI, Stenling R, Roos G. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol. 1999;36:565–9.

    Article  PubMed  CAS  Google Scholar 

  19. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604–14.

    Article  PubMed  CAS  Google Scholar 

  20. Onishi T, Ohishi Y, Goto H, Suzuki M, Miyazawa Y. Papillary renal cell carcinoma: clinicopathological characteristics and evaluation of prognosis in 42 patients. BJU Int. 1999;83:937–43.

    Article  PubMed  CAS  Google Scholar 

  21. Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008;102:1381–4.

    PubMed  Google Scholar 

  22. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.

    Article  PubMed  Google Scholar 

  23. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008;112:1480–8.

    Article  PubMed  Google Scholar 

  24. Ficarra V, Martignoni G, Galfano A, et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol. 2006;50:786–93.

    Article  PubMed  Google Scholar 

  25. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol. 2005;48:593–600.

    Article  PubMed  Google Scholar 

  26. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25:1316–22.

    Article  PubMed  Google Scholar 

  27. Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012;188:391–7.

    Article  PubMed  Google Scholar 

  28. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009;103:1496–500.

    Article  PubMed  Google Scholar 

  29. • Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–15. This is a recent large single-institution study showing a positive prognotic effect of papillary RCC compared with clear cell RCC histologic subtype by multivariate analysis.

    Article  PubMed  Google Scholar 

  30. • Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - a multicentre study. Eur J Cancer. 2012;48:2347–52. This is a recent large multicenter study comparing papillary RCC and clear cell RCC subtypes. The papillary subtype was found to have a significant positive effect in localized disease but a negative effect in metastatic disease by multivariate analysis. Both [29] and [30] are studies in large numbers of patients and used either a single pathologist or a dedicated group of genitourinary pathologists for slide review. Most of the other cited studies were smaller and did not have dedicated pathology review.

    Article  PubMed  Google Scholar 

  31. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537–44.

    PubMed  CAS  Google Scholar 

  32. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–5.

    Article  PubMed  CAS  Google Scholar 

  33. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15:1162–9.

    Article  PubMed  CAS  Google Scholar 

  34. Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A. Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virchows Arch. 2003;442:336–42.

    PubMed  Google Scholar 

  35. Antonelli A, Tardanico R, Balzarini P, et al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet. 2010;199:128–33.

    Article  PubMed  CAS  Google Scholar 

  36. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764–7.

    Article  PubMed  Google Scholar 

  37. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69:230–5.

    Article  PubMed  Google Scholar 

  38. Gontero P, Ceratti G, Guglielmetti S, et al. Prognostic factors in a prospective series of papillary renal cell carcinoma. BJU Int. 2008;102:697–702.

    Article  PubMed  Google Scholar 

  39. Ku JH, Moon KC, Kwak C, Kim HH, Lee SE. Is there a role of the histologic subtypes of papillary renal cell carcinoma as a prognostic factor? Jpn J Clin Oncol. 2009;39:664–70.

    Article  PubMed  Google Scholar 

  40. Klatte T, Remzi M, Zigeuner RE, et al. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol. 2010;184:53–8.

    Article  PubMed  Google Scholar 

  41. Sukov WR, Lohse CM, Leibovich BC, Thompson RH, Cheville JC. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol. 2012;187:54–9.

    Article  PubMed  Google Scholar 

  42. Zbar B, Glenn G, Lubensky I, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol. 1995;153:907–12.

    Article  PubMed  CAS  Google Scholar 

  43. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–6.

    PubMed  CAS  Google Scholar 

  44. Bentz M, Bergerheim US, Li C, et al. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet. 1996;75:17–21.

    Article  PubMed  CAS  Google Scholar 

  45. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.

    Article  PubMed  CAS  Google Scholar 

  46. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58:1719–22.

    PubMed  CAS  Google Scholar 

  47. Fischer J, Palmedo G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene. 1998;17:733–9.

    Article  PubMed  CAS  Google Scholar 

  48. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet. 1998;20:66–9.

    Article  PubMed  CAS  Google Scholar 

  49. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 1997;94:11445–50.

    Article  PubMed  CAS  Google Scholar 

  50. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–50.

    Article  PubMed  CAS  Google Scholar 

  51. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517–26.

    Article  PubMed  CAS  Google Scholar 

  52. Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol. 2002;168:51–5.

    Article  PubMed  CAS  Google Scholar 

  53. Linehan WM, Pinto PA, Bratslavsky G, et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer. 2009;115:2252–61.

    Article  PubMed  CAS  Google Scholar 

  54. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13:671s–9s.

    Article  PubMed  CAS  Google Scholar 

  55. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S–9S.

    Article  PubMed  CAS  Google Scholar 

  56. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106.

    Article  PubMed  CAS  Google Scholar 

  57. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.

    Article  PubMed  CAS  Google Scholar 

  58. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972–80.

    PubMed  CAS  Google Scholar 

  59. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  PubMed  CAS  Google Scholar 

  60. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.

    Article  PubMed  CAS  Google Scholar 

  61. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  PubMed  CAS  Google Scholar 

  62. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  PubMed  CAS  Google Scholar 

  63. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.

    Article  PubMed  CAS  Google Scholar 

  64. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33.

    Article  PubMed  CAS  Google Scholar 

  65. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA. 1987;84:6379–83.

    Article  PubMed  CAS  Google Scholar 

  66. Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989;163:967–73.

    Article  PubMed  CAS  Google Scholar 

  67. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–3.

    Article  PubMed  CAS  Google Scholar 

  68. Zarnegar R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 1989;49:3314–20.

    PubMed  CAS  Google Scholar 

  69. Gherardi E, Gray J, Stoker M, Perryman M, Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci USA. 1989;86:5844–8.

    Article  PubMed  CAS  Google Scholar 

  70. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–42.

    Article  PubMed  CAS  Google Scholar 

  71. Gherardi E, Stoker M. Hepatocytes and scatter factor. Nature. 1990;346:228.

    Article  PubMed  CAS  Google Scholar 

  72. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991;88:7001–5.

    Article  PubMed  CAS  Google Scholar 

  73. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–4.

    Article  PubMed  CAS  Google Scholar 

  74. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.

    Article  PubMed  CAS  Google Scholar 

  75. •• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103. This is an extensive and up-to-date review of MET and the MET pathway and the rationale for targeting it in cancer therapy.

    Article  PubMed  CAS  Google Scholar 

  76. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006;20:1611–21.

    Article  PubMed  CAS  Google Scholar 

  77. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 2008;44:641–51.

    Article  PubMed  CAS  Google Scholar 

  78. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–61.

    Article  PubMed  Google Scholar 

  79. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene. 2000;19:2212–23.

    Article  PubMed  CAS  Google Scholar 

  80. Migliore C, Martin V, Leoni VP, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2012;18:737–47.

    Article  PubMed  CAS  Google Scholar 

  81. •• Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9:314–26. This is a timely and extensive review of the MET pathway and the drugs currently under development which target it.

    Article  PubMed  CAS  Google Scholar 

  82. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.

    Article  PubMed  CAS  Google Scholar 

  83. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1–26.

    Article  PubMed  CAS  Google Scholar 

  84. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15:2207–14.

    Article  PubMed  CAS  Google Scholar 

  85. •• Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16:3507–16. This is a phase I study of foretinib in 40 cancer patients. Two papillary RCC patients responded.

    Article  PubMed  CAS  Google Scholar 

  86. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69:8009–16.

    Article  PubMed  CAS  Google Scholar 

  87. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003;423:593–5.

    Article  PubMed  CAS  Google Scholar 

  88. Sennino B, Naylor RM, Tabruyn SP. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-TAG2 mice after inhibition of VEGFR plus C-met by XL184. Mol Cancer Ther. 2009;8(12 Suppl):A13.

    Article  Google Scholar 

  89. You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71:4758–68.

    Article  PubMed  CAS  Google Scholar 

  90. Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 2012;15:59–70.

    Article  PubMed  CAS  Google Scholar 

  91. Kataoka Y, Mukohara T, Tomioka H, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012;30:1352–60.

    Article  PubMed  CAS  Google Scholar 

  92. Liu L, Shi H, Liu Y, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther. 2011;10:518–30.

    Article  PubMed  CAS  Google Scholar 

  93. Zillhardt M, Park SM, Romero IL, et al. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011;17:4042–51.

    Article  PubMed  CAS  Google Scholar 

  94. Shapiro GI, Heath E, Malburg L. A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, A VEGFR and MET kinase inhibitor, administered daily to patients with advanced malignancies. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting 2007 abstract B248.

  95. Naing A, Kurzrock R, Adams LM, et al. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2012;30:327–34.

    Article  PubMed  CAS  Google Scholar 

  96. •• Choueiri TK, Vaishampayan U, Rosenberg JE, et al. A phase II and biomarker study of the dual MET/VEGFR-2 inhibitor foretinib in patients with papillary renal cell cancer. J Clin Oncol. 2013;31:181–6. This is the phase II study of foretinib in papillary RCC.

    Article  PubMed  CAS  Google Scholar 

  97. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

    Article  PubMed  CAS  Google Scholar 

  98. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107:2617–21.

    Article  PubMed  CAS  Google Scholar 

  99. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127–31.

    Article  PubMed  CAS  Google Scholar 

  100. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009;7:39–42.

    Article  PubMed  CAS  Google Scholar 

  101. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009;27:5788–93.

    Article  PubMed  CAS  Google Scholar 

  102. Tsimafeyeu I, Demidov L, Kharkevich G, et al. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol. 2012;35:251–4.

    Article  PubMed  CAS  Google Scholar 

  103. Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012;62:1013–9.

    Article  PubMed  CAS  Google Scholar 

  104. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2012;30:335–40.

    Article  PubMed  CAS  Google Scholar 

  105. Lee J, Ahn J, Lim H. Multicenter prospective phase II study of sunitinib in non-clear cell type renal cell carcinoma. J Clin Oncol. 2011;29(Suppl 7):abstr 325.

  106. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26:202–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Disclosure T. F. Logan: consultant to Argos, Bristol-Myers-Squibb, Celgene, Genentech, GlaxoSmithKline, Novartis, Pfizer, Prometheus, Wyeth, and Aveo and speakers’ bureaus for Bristol-Myers-Squibb, Prometheus, Pfizer, GlaxoSmithKline, Wyeth, and Novartis.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, IU Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN, 46202, USA

    Theodore F. Logan

Authors
  1. Theodore F. Logan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodore F. Logan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Logan, T.F. Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer. Curr Oncol Rep 15, 83–90 (2013). https://doi.org/10.1007/s11912-013-0299-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-013-0299-3

Keywords

Search

Navigation